CoChat

Regulation of miRNAs Expression by Mutant p53 Gain of Function in Cancer

Madrigal, Tzitzijanik, Hernández-Monge, Jesús, Herrera, Luis A, González-De la Rosa, Claudia Haydée, Domínguez-Gómez, Guadalupe, Candelaria, Myrna, Luna-Maldonado, Fernando, Calderón González, Karla G, Díaz-Chávez, José · 2021 · Frontiers in Cell and Developmental Biology
Cited by 17

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

The p53 roles have been largely described; among them, cell proliferation and apoptosis control are some of the best studied and understood. Interestingly, the mutations on the six hotspot sites within the region that encodes the DNA-binding domain of p53 give rise to other very different variants. The particular behavior of these variants led to consider p53 mutants as separate oncogene entities; that is, they do not retain wild type functions but acquire new ones, namely Gain-of-function p53 mutants. Furthermore, recent studies have revealed how p53 mutants regulate gene expression and exert oncogenic effects by unbalancing specific microRNAs (miRNAs) levels that provoke epithelial-mesenchymal transition, chemoresistance, and cell survival, among others. In this review, we discuss recent evidence of the crosstalk between miRNAs and mutants of p53, as well as the consequent cellular processes dysregulated.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fcell.2021.695723

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 99

  1. Abdelmohsen, 2010, miR-519 Suppresses Tumor Growth by Reducing HuR Levels, Cell Cycle, 9, 1354, 10.4161/cc.9.7.11164 · DOI · Paper page
  2. Ahn, 1999, Down-regulation of the stathmin/Op18 and FKBP25 Genes Following P53 Induction, Oncogene, 18, 5954, 10.1038/sj.onc.1202986 · DOI
  3. Bornachea, 2012, EMT and Induction of miR-21 Mediate Metastasis Development in Trp53-Deficient Tumours, Sci. Rep., 2, 434, 10.1038/srep00434 · DOI
  4. Boyerinas, 2010, The Role of Let-7 in Cell Differentiation and Cancer, Endocr. Relat. Cancer, 17, F19, 10.1677/erc-09-0184 · DOI · Paper page
  5. Bullock, 2001, Rescuing the Function of Mutant P53, Nat. Rev. Cancer, 1, 68, 10.1038/35094077 · DOI · Paper page
  6. Buonfiglioli, 2019, let-7 MicroRNAs Regulate Microglial Function and Suppress Glioma Growth through Toll-like Receptor 7, Cel Rep., 29, 3460, 10.1016/j.celrep.2019.11.029 · DOI · Paper page
  7. Calin, 2006, MicroRNA Signatures in Human Cancers, Nat. Rev. Cancer, 6, 857, 10.1038/nrc1997 · DOI · Paper page
  8. Capaci, 2020, Mutant P53 Induces Golgi Tubulo-Vesiculation Driving a Prometastatic Secretome, Nat. Commun., 11, 3945, 10.1038/s41467-020-17596-5 · DOI · Paper page
  9. Chang, 2013, Acetylation of P53 Stimulates miRNA Processing and Determines Cell Survival Following Genotoxic Stress, Embo j, 32, 3192, 10.1038/emboj.2013.242 · DOI
  10. Chirshev, 2019, Let-7 as Biomarker, Prognostic Indicator, and Therapy for Precision Medicine in Cancer, Clin. Transl Med., 8, 24, 10.1186/s40169-019-0240-y · DOI · Paper page
  11. Cimmino, 2005, miR-15 and miR-16 Induce Apoptosis by Targeting BCL2, Proc. Natl. Acad. Sci., 102, 13944, 10.1073/pnas.0506654102 · DOI · Paper page
  12. Citron, 2020, Downregulation of miR-223 Expression Is an Early Event during Mammary Transformation and Confers Resistance to CDK4/6 Inhibitors in Luminal Breast Cancer, Cancer Res., 80, 1064, 10.1158/0008-5472.can-19-1793 · DOI · Paper page
  13. Croce, 2009, Causes and Consequences of microRNA Dysregulation in Cancer, Nat. Rev. Genet., 10, 704, 10.1038/nrg2634 · DOI · Paper page
  14. Denli, 2004, Processing of Primary microRNAs by the Microprocessor Complex, Nature, 432, 231, 10.1038/nature03049 · DOI · Paper page
  15. Di Agostino, 2020, The Impact of Mutant P53 in the Non-coding RNA World, Biomolecules, 10, 472, 10.3390/biom10030472 · DOI
  16. Dong, 2013, Mutant P53 Gain-Of-Function Induces Epithelial-Mesenchymal Transition through Modulation of the miR-130b-ZEB1 axis, Oncogene, 32, 3286, 10.1038/onc.2012.334 · DOI · Paper page
  17. Donzelli, 2012, MicroRNA-128-2 Targets the Transcriptional Repressor E2F5 Enhancing Mutant P53 Gain of Function, Cell Death Differ, 19, 1038, 10.1038/cdd.2011.190 · DOI
  18. Donzelli, 2014, microRNAs: Short Non-coding Bullets of Gain of Function Mutant P53 Proteins, Oncoscience, 1, 427, 10.18632/oncoscience.52 · DOI
  19. Du, 2019, miR-517a Is Up-Regulated in Glioma and Promotes Glioma Tumorigenesis In Vitro and In Vivo, Biosci. Rep., 39, 10.1042/BSR20181196 · DOI
  20. Fort, 2018, An Integrated View of the Role of miR-130b/301b miRNA Cluster in Prostate Cancer, Exp. Hematol. Oncol., 7, 10, 10.1186/s40164-018-0102-0 · DOI
  21. Ganci, 2013, Expression of TP53 Mutation-Associated microRNAs Predicts Clinical Outcome in Head and Neck Squamous Cell Carcinoma Patients, Ann. Oncol., 24, 3082, 10.1093/annonc/mdt380 · DOI
  22. Gao, 2020, Exosomal Transfer of Macrophage-Derived miR-223 Confers Doxorubicin Resistance in Gastric Cancer, Ott, 12169, 10.2147/ott.s283542 · DOI
  23. Gao, 2020, MicroRNA-105 Plays an Independent Prognostic Role in Esophageal Cancer and Acts as an Oncogene, Cbm, 27, 173, 10.3233/cbm-190736 · doi:10.3233/cbm-190736
  24. Garibaldi, 2016, Mutant P53 Inhibits miRNA Biogenesis by Interfering with the Microprocessor Complex, Oncogene, 35, 3760, 10.1038/onc.2016.51 · DOI
  25. Garibaldi, 2016, Mutant P53 Inhibits miRNA Biogenesis by Interfering with the Microprocessor Complex, Oncogene, 35, 3760, 10.1038/onc.2016.51 · DOI
  26. Gasparini, 2014, Protective Role of miR-155 in Breast Cancer through RAD51 Targeting Impairs Homologous Recombination after Irradiation, Proc. Natl. Acad. Sci., 111, 4536, 10.1073/pnas.1402604111 · DOI · Paper page
  27. Gu, 2016, miR-27a Attenuates Adipogenesis and Promotes Osteogenesis in Steroid-Induced Rat BMSCs by Targeting PPARγ and GREM1, Sci. Rep., 6, 38491, 10.1038/srep38491 · DOI
  28. Gurtner, 2016, Dysregulation of microRNA Biogenesis in Cancer: the Impact of Mutant P53 on Drosha Complex Activity, J. Exp. Clin. Cancer Res., 35, 45, 10.1186/s13046-016-0319-x · DOI
  29. Ha, 2014, Regulation of microRNA Biogenesis, Nat. Rev. Mol. Cel Biol, 15, 509, 10.1038/nrm3838 · DOI · Paper page
  30. Hainaut, 2000, p53 and Human Cancer: the First Ten Thousand Mutations, Adv. Cancer Res., 77, 81, 10.1016/s0065-230x(08)60785-x · DOI · Paper page
  31. Halcrow, 2021, Overcoming Chemoresistance: Altering pH of Cellular Compartments by Chloroquine and Hydroxychloroquine, Front. Cel Dev. Biol., 9, 627639, 10.3389/fcell.2021.627639 · DOI
  32. Hertel, 2012, Evolution of the Let-7 microRNA Family, RNA Biol., 9, 231, 10.4161/rna.18974 · DOI · Paper page
  33. Hirono, 2019, MicroRNA-130b Functions as an oncomiRNA in Non-small Cell Lung Cancer by Targeting Tissue Inhibitor of Metalloproteinase-2, Sci. Rep., 9, 6956, 10.1038/s41598-019-43355-8 · DOI
  34. Hu, 2018, MiR-27b Impairs Adipocyte Differentiation of Human Adipose Tissue-Derived Mesenchymal Stem Cells by Targeting LPL, Cell Physiol Biochem, 47, 545, 10.1159/000489988 · doi:10.1159/000489988
  35. Hu, 2019, Aberrant Expression and Mechanism of miR-130b-3p/phosphatase and Tensin Homolog in Nephroblastoma in Children, Exp. Ther. Med., 18, 1021, 10.3892/etm.2019.7643 · DOI
  36. Huang, 2015, miR-128 Как Ключевой Регулятор онкогенности, Молекул. биол., 49, 46, 10.7868/s0026898415010061 · DOI
  37. Jansson, 2012, MicroRNA and Cancer, Mol. Oncol., 6, 590, 10.1016/j.molonc.2012.09.006 · DOI · Paper page
  38. Jiang, 2015, Mutant P53 Induces EZH2 Expression and Promotes Epithelial-Mesenchymal Transition by Disrupting P68-Drosha Complex Assembly and Attenuating miR-26a Processing, Oncotarget, 6, 44660, 10.18632/oncotarget.6350 · DOI
  39. Jin, 2019, Up-regulation of miRNA-105 Inhibits the Progression of Gastric Carcinoma by Directly Targeting SOX9, Eur. Rev. Med. Pharmacol. Sci., 23, 3779, 10.26355/eurrev_201905_17804 · doi:10.26355/eurrev_201905_17804
  40. Jin, 2016, FXR1 Is Elevated in Colorectal Cancer and Acts as an Oncogene, Tumor Biol., 37, 2683, 10.1007/s13277-015-4068-9 · DOI
  41. Jones, 2012, MicroRNAs, Wild-type and Mutant P53: More Questions Than Answers, RNA Biol., 9, 781, 10.4161/rna.20146 · DOI · Paper page
  42. Kim, 2010, miR-27a Is a Negative Regulator of Adipocyte Differentiation via Suppressing PPARγ Expression, Biochem. Biophysical Res. Commun., 392, 323, 10.1016/j.bbrc.2010.01.012 · DOI · Paper page
  43. Kumar, 2008, CBFA2T3-ZNF652 Corepressor Complex Regulates Transcription of the E-Box Gene HEB, J. Biol. Chem., 283, 19026, 10.1074/jbc.m709136200 · DOI
  44. Kumar, 2006, ZNF652, a Novel Zinc finger Protein, Interacts with the Putative Breast Tumor Suppressor CBFA2T3 to Repress Transcription, Mol. Cancer Res., 4, 655, 10.1158/1541-7786.mcr-05-0249 · DOI
  45. Landi, 2013, Irreversible EGFR-TKIs: Dreaming Perfection, Transl Lung Cancer Res., 2, 40, 10.3978/j.issn.2218-6751.2012.12.05 · DOI
  46. Li, 2014, Deregulation of miR-128 in Ovarian Cancer Promotes Cisplatin Resistance, Int. J. Gynecol. Cancer, 24, 1381, 10.1097/igc.0000000000000252 · DOI
  47. Li, 2013, miR-128 and its Target Genes in Tumorigenesis and Metastasis, Exp. Cel Res., 319, 3059, 10.1016/j.yexcr.2013.07.031 · DOI · Paper page
  48. Li, 2014, Mutant P53 Exerts Oncogenic Effects through microRNAs and Their Target Gene Networks, FEBS Lett., 588, 2610, 10.1016/j.febslet.2014.03.054 · DOI
  49. Li, 2020, Bmi-1-induced miR-27a and miR-155 Promote Tumor Metastasis and Chemoresistance by Targeting RKIP in Gastric Cancer, Mol. Cancer, 19, 109, 10.1186/s12943-020-01229-y · DOI
  50. Lian, 2018, miR-128 Targets the SIRT1/ROS/DR5 Pathway to Sensitize Colorectal Cancer to TRAIL-Induced Apoptosis, Cel Physiol Biochem, 49, 2151, 10.1159/000493818 · DOI · Paper page
  51. Liu, 2018, MicroRNA-155 Acts as a Tumor Suppressor in Colorectal Cancer by Targeting CTHRC1 In Vitro, Oncol. Lett., 15, 5561, 10.3892/ol.2018.8069 · DOI
  52. Liu, 2013, Down-regulation of miR-517a and miR-517c Promotes Proliferation of Hepatocellular Carcinoma Cells via Targeting Pyk2, Cancer Lett., 329, 164, 10.1016/j.canlet.2012.10.027 · DOI
  53. Liu, 2017, Exosomes Containing miR-21 Transfer the Characteristic of Cisplatin Resistance by Targeting PTEN and PDCD4 in Oral Squamous Cell Carcinoma, Acta Biochim. Biophys. Sin (Shanghai), 49, 808, 10.1093/abbs/gmx078 · DOI · Paper page
  54. Liu, 2019, Exosome-transmitted miR-128-3p Increase Chemosensitivity of Oxaliplatin-Resistant Colorectal Cancer, Mol. Cancer, 18, 43, 10.1186/s12943-019-0981-7 · DOI · Paper page
  55. Liu, 2020, Nanocomplexes Loaded with miR-128-3p for Enhancing Chemotherapy Effect of Colorectal Cancer through Dual-Targeting Silence the Activity of PI3K/AKT and MEK/ERK Pathway, Drug Deliv., 27, 323, 10.1080/10717544.2020.1716882 · DOI
  56. Liu, 2021, MicroRNA223induced Inhibition of the FBXW7 Gene Affects the Proliferation and Apoptosis of Colorectal Cancer Cells via the Notch and Akt/mTOR Pathways, Mol. Med. Rep., 23, 154, 10.3892/mmr.2020.11793 · DOI
  57. Ma, 2016, miR-517a Is an Independent Prognostic Marker and Contributes to Cell Migration and Invasion in Human Colorectal Cancer, Oncol. Lett., 11, 2583, 10.3892/ol.2016.4269 · DOI
  58. Maleki, 2021, The Role of Extracellular Vesicles in Mediating Resistance to Anticancer Therapies, Int. J. Mol. Sci., 22, 4166, 10.3390/ijms22084166 · DOI
  59. Masciarelli, 2014, Gain-of-function Mutant P53 Downregulates miR-223 Contributing to Chemoresistance of Cultured Tumor Cells, Oncogene, 33, 1601, 10.1038/onc.2013.106 · DOI · Paper page
  60. Mashima, 2015, Physiological Roles of miR-155, Immunology, 145, 323, 10.1111/imm.12468 · DOI · Paper page
  61. Masood, 2019, Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer Harboring Uncommon EGFR Mutations: Focus on Afatinib, Semin. Oncol., 46, 271, 10.1053/j.seminoncol.2019.08.004 · DOI
  62. Mello, 2013, Not all P53 Gain-Of-Function Mutants Are Created Equal, Cel Death Differ, 20, 855, 10.1038/cdd.2013.53 · DOI · Paper page
  63. Miura, 2010, Identification of Pregnancy-Associated microRNAs in Maternal Plasma, Clin. Chem., 56, 1767, 10.1373/clinchem.2010.147660 · DOI · Paper page
  64. Mizuno, 2018, The Molecular Basis and Therapeutic Potential of Let-7 MicroRNAs against Colorectal Cancer, Can. J. Gastroenterol. Hepatol., 2018, 5769591, 10.1155/2018/5769591 · DOI · Paper page
  65. Muller, 2014, Mutant P53 Regulates Dicer through P63-dependent and -independent Mechanisms to Promote an Invasive Phenotype, J. Biol. Chem., 289, 122, 10.1074/jbc.m113.502138 · DOI · Paper page
  66. Neilsen, 2013, Mutant P53 Drives Invasion in Breast Tumors through Up-Regulation of miR-155, Oncogene, 32, 2992, 10.1038/onc.2012.305 · DOI · Paper page
  67. O'Brien, 2018, Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation, Front. Endocrinol., 9, 402, 10.3389/fendo.2018.00402 · DOI · Paper page
  68. Phadke, 2011, In vivoSafety and Antitumor Efficacy of Bifunctional Small Hairpin RNAs Specific for the Human Stathmin 1 Oncoprotein, DNA Cel Biol., 30, 715, 10.1089/dna.2011.1240 · DOI
  69. Rana, 2008, Stathmin 1: a Novel Therapeutic Target for Anticancer Activity, Expert Rev. Anticancer Ther., 8, 1461, 10.1586/14737140.8.9.1461 · DOI · Paper page
  70. Russo, 2017, Third Generation EGFR TKIs in EGFR-Mutated NSCLC: Where Are We Now and where Are We Going, Crit. Rev. Oncology/Hematology, 117, 38, 10.1016/j.critrevonc.2017.07.003 · DOI
  71. Saito, 2015, microRNA-34a as a Therapeutic Agent against Human Cancer, Jcm, 4, 1951, 10.3390/jcm4111951 · DOI
  72. Shang, 2019, MiR-105 Inhibits Gastric Cancer Cells Metastasis, Epithelial-Mesenchymal Transition by Targeting SOX9, Eur. Rev. Med. Pharmacol. Sci., 23, 6160, 10.26355/eurrev_201907_18429 · doi:10.26355/eurrev_201907_18429
  73. She, 2014, miR-128 and miR-149 Enhance the Chemosensitivity of Temozolomide by Rap1B-Mediated Cytoskeletal Remodeling in Glioblastoma, Oncol. Rep., 32, 957, 10.3892/or.2014.3318 · DOI · Paper page
  74. Strano, 2007, Mutant P53 Proteins: between Loss and Gain of Function, Head Neck, 29, 488, 10.1002/hed.20531 · DOI · Paper page
  75. Su, 2019, miR-27a-3p Regulates Proliferation and Apoptosis of colon Cancer Cells by Potentially Targeting BTG1, Oncol. Lett., 18, 2825, 10.3892/ol.2019.10629 · DOI
  76. Subramanian, 2015, A Mutant p53/let-7i-axis-regulated Gene Network Drives Cell Migration, Invasion and Metastasis, Oncogene, 34, 1094, 10.1038/onc.2014.46 · DOI · Paper page
  77. Sun, 2008, Proline-rich Tyrosine Kinase 2 (Pyk2) Promotes Proliferation and Invasiveness of Hepatocellular Carcinoma Cells through C-Src/ERK Activation, Carcinogenesis, 29, 2096, 10.1093/carcin/bgn203 · DOI
  78. Sun, 2013, Diverse Functions of miR-125 Family in Different Cell Contexts, J. Hematol. Oncol., 6, 6, 10.1186/1756-8722-6-6 · DOI · Paper page
  79. Sun, 2019, miR-27a Regulates Vascular Remodeling by Targeting Endothelial Cells' Apoptosis and Interaction with Vascular Smooth Muscle Cells in Aortic Dissection, Theranostics, 9, 7961, 10.7150/thno.35737 · DOI
  80. Suzuki, 2009, Modulation of microRNA Processing by P53, Nature, 460, 529, 10.1038/nature08199 · DOI · Paper page
  81. Svoronos, 2016, OncomiR or Tumor Suppressor? the Duplicity of MicroRNAs in Cancer, Cancer Res., 76, 3666, 10.1158/0008-5472.can-16-0359 · DOI · Paper page
  82. Tang, 2014, miR-27a Regulates Endothelial Differentiation of Breast Cancer Stem like Cells, Oncogene, 33, 2629, 10.1038/onc.2013.214 · DOI
  83. Tie, 2010, MiR-218 Inhibits Invasion and Metastasis of Gastric Cancer by Targeting the Robo1 Receptor, Plos Genet., 6, e1000879, 10.1371/journal.pgen.1000879 · DOI · Paper page
  84. Tu, 2013, MicroRNA-218 Inhibits Glioma Invasion, Migration, Proliferation, and Cancer Stem-like Cell Self-Renewal by Targeting the Polycomb Group Gene Bmi1, Cancer Res., 73, 6046, 10.1158/0008-5472.can-13-0358 · DOI · Paper page
  85. Valenti, 2019, The miR-205-5p/BRCA1/RAD17 Axis Promotes Genomic Instability in Head and Neck Squamous Cell Carcinomas, Cancers (Basel), 11, 1347, 10.3390/cancers11091347 · DOI
  86. Vasudevan, 2007, Switching from Repression to Activation: microRNAs Can Up-Regulate Translation, Science, 318, 1931, 10.1126/science.1149460 · DOI · Paper page
  87. Vigorito, 2013, miR-155: an Ancient Regulator of the Immune System, Immunol. Rev., 253, 146, 10.1111/imr.12057 · DOI · Paper page
  88. Walerych, 2016, Proteasome Machinery Is Instrumental in a Common Gain-Of-Function Program of the P53 Missense Mutants in Cancer, Nat. Cel Biol, 18, 897, 10.1038/ncb3380 · DOI · Paper page
  89. Wang, 2020, MiR-223 Regulates Autophagy Associated with Cisplatin Resistance by Targeting FBXW7 in Human Non-small Cell Lung Cancer, Cancer Cel Int, 20, 258, 10.1186/s12935-020-01284-x · DOI
  90. Wang, 2015, Correlation of Increased Expression of MicroRNA-155 in Bladder Cancer and Prognosis, Lab. Med., 46, 118, 10.1309/lmwr9cea2k2xvsox · DOI
  91. Wang, 2013, Mutant P53-R273h Gains New Function in Sustained Activation of EGFR Signaling via Suppressing miR-27a Expression, Cell Death Dis, 4, e574, 10.1038/cddis.2013.97 · DOI
  92. Xu, 2013, miR-24-3p and miR-27a-3p Promote Cell Proliferation in Glioma Cells via Cooperative Regulation of MXI1, Int. J. Oncol., 42, 757, 10.3892/ijo.2012.1742 · DOI · Paper page
  93. Yang, 2020, Silencing of microRNA-517a Induces Oxidative Stress Injury in Melanoma Cells via Inactivation of the JNK Signaling Pathway by Upregulating CDKN1C, Cancer Cel Int, 20, 32, 10.1186/s12935-019-1064-y · DOI
  94. Ye, 2018, Role of miR-223 in the Pathophysiology of Liver Diseases, Exp. Mol. Med., 50, 128, 10.1038/s12276-018-0153-7 · DOI · Paper page
  95. Yoshitomi, 2011, Restoration of miR-517a Expression Induces Cell Apoptosis in Bladder Cancer Cell Lines, Oncol. Rep., 25, 1661, 10.3892/or.2011.1253 · doi:10.3892/or.2011.1253
  96. You, 2016, MiR-27a Is Essential for the Shift from Osteogenic Differentiation to Adipogenic Differentiation of Mesenchymal Stem Cells in Postmenopausal Osteoporosis, Cel Physiol Biochem, 39, 253, 10.1159/000445621 · DOI
  97. Zhang, 2016, Gain-of-function miRNA Signature by Mutant P53 Associates with Poor Cancer Outcome, Oncotarget, 7, 11056, 10.18632/oncotarget.7090 · DOI
  98. Zhao, 2013, MiR-130b Is a Prognostic Marker and Inhibits Cell Proliferation and Invasion in Pancreatic Cancer through Targeting STAT3, PLoS One, 8, e73803, 10.1371/journal.pone.0073803 · DOI
  99. Zhou, 2018, MicroRNA-223 Suppresses the Canonical NF-Κb Pathway in Basal Keratinocytes to Dampen Neutrophilic Inflammation, Cel Rep., 22, 1810, 10.1016/j.celrep.2018.01.058 · DOI · Paper page

Cited by

See all 17

Metadata

Authors
Madrigal, T., Hernández-Monge, J., Herrera, L. A., González-De la Rosa, C. H., Domínguez-Gómez, G., Candelaria, M., Luna-Maldonado, F., Calderón González, K. G., & Díaz-Chávez, J.
Venue
Frontiers in Cell and Developmental Biology
Published
2021-12-06
Volume
9
ISSN
2296-634X
Cited by
17
References
8
Funders
Consejo Nacional de Ciencia y Tecnología (168896 261875)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.